As an example, although the CH origin of the mutation is of little doubt when it affects genes such as DNMT3A, TET2, ASXL1 or JAK2 [58], the situation is less clear for classical oncogenic drivers such as KRAS or common tumor suppressors such as TP53. Indeed, KRAS mutations usually found in pancreatic [59], colorectal [60] or lung cancer [61] are also frequently identified in cfDNA analysis. This evidence concerns the gene TP53 and neoplasm.